** Shares of telehealth firm Hims and Hers HIMS.N, which offers compounded versions of weight-loss drugs, fall 20.4% to $52.8
** The U.S FDA says that a shortage of Novo Nordisk's NOVOb.CO weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved as per the agency's website
** The resolution could restrict how telehealth programs offer cheaper versions known as compounded drugs
** For HIMS and other compounders "this development starts the clock on having unfettered market access" to Novo's drugs, says brokerage Leerink Partners
** It will be critical to understand HIMS' legal pathway to selling personalized doses for semaglutide - since it is the primary way it can continue selling the drug, Leerink added
** US government regulations allow compounded versions of a branded drug to be sold to meet demand if the drug is in shortage
** Stock has risen nearly seven-fold in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。